» Articles » PMID: 23711983

Increasing Dopamine D2 Receptor Expression in the Adult Nucleus Accumbens Enhances Motivation

Overview
Journal Mol Psychiatry
Date 2013 May 29
PMID 23711983
Citations 90
Authors
Affiliations
Soon will be listed here.
Abstract

A decrease in dopamine D2 receptor (D2R) binding in the striatum is one of the most common findings in disorders that involve a dysregulation of motivation, including obesity, addiction and attention deficit hyperactivity disorder. As disruption of D2R signaling in the ventral striatum--including the nucleus accumbens (NAc)--impairs motivation, we sought to determine whether potentiating postsynaptic D2R-dependent signaling in the NAc would improve motivation. In this study, we used a viral vector strategy to overexpress postsynaptic D2Rs in either the NAc or the dorsal striatum. We investigated the effects of D2R overexpression on instrumental learning, willingness to work, use of reward value representations and modulation of motivation by reward associated cues. Overexpression of postsynaptic D2R in the NAc selectively increased motivation without altering consummatory behavior, the representation of the value of the reinforcer, or the capacity to use reward associated cues in flexible ways. In contrast, D2R overexpression in the dorsal striatum did not alter performance on any of the tasks. Thus, consistent with numerous studies showing that reduced D2R signaling impairs motivated behavior, our data show that postsynaptic D2R overexpression in the NAc specifically increases an animal's willingness to expend effort to obtain a goal. Taken together, these results provide insight into the potential impact of future therapeutic strategies that enhance D2R signaling in the NAc.

Citing Articles

Inhibition of striatal indirect pathway during second postnatal week leads to long-lasting deficits in motivated behavior.

Olivetti P, Torres-Herraez A, Gallo M, Raudales R, Sumerau M, Moyles S Neuropsychopharmacology. 2024; 50(4):651-661.

PMID: 39327472 PMC: 11845773. DOI: 10.1038/s41386-024-01997-x.


The nucleus accumbens in reward and aversion processing: insights and implications.

Xu Y, Lin Y, Yu M, Zhou K Front Behav Neurosci. 2024; 18:1420028.

PMID: 39184934 PMC: 11341389. DOI: 10.3389/fnbeh.2024.1420028.


Decoding Post-Viral Fatigue: The Basal Ganglia's Complex Role in Long-COVID.

Rudroff T Neurol Int. 2024; 16(2):380-393.

PMID: 38668125 PMC: 11054322. DOI: 10.3390/neurolint16020028.


Orexins/Hypocretins: Gatekeepers of Social Interaction and Motivation.

Ouaidat S, Amaral I, Monteiro D, Harati H, Hofer A, El Rawas R Int J Mol Sci. 2024; 25(5).

PMID: 38473854 PMC: 10931973. DOI: 10.3390/ijms25052609.


Cannabidiol and brain function: current knowledge and future perspectives.

Schouten M, Dalle S, Mantini D, Koppo K Front Pharmacol. 2024; 14:1328885.

PMID: 38288087 PMC: 10823027. DOI: 10.3389/fphar.2023.1328885.


References
1.
Zhang M, Balmadrid C, Kelley A . Nucleus accumbens opioid, GABaergic, and dopaminergic modulation of palatable food motivation: contrasting effects revealed by a progressive ratio study in the rat. Behav Neurosci. 2003; 117(2):202-11. DOI: 10.1037/0735-7044.117.2.202. View

2.
Nikolaus S, Antke C, Beu M, Muller H . Cortical GABA, striatal dopamine and midbrain serotonin as the key players in compulsive and anxiety disorders--results from in vivo imaging studies. Rev Neurosci. 2010; 21(2):119-39. DOI: 10.1515/revneuro.2010.21.2.119. View

3.
Koob G . Hedonic valence, dopamine and motivation. Mol Psychiatry. 1996; 1(3):186-9. View

4.
Kellendonk C, Simpson E, Polan H, Malleret G, Vronskaya S, Winiger V . Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron. 2006; 49(4):603-15. DOI: 10.1016/j.neuron.2006.01.023. View

5.
Mott A, Nunes E, Collins L, Port R, Sink K, Hockemeyer J . The adenosine A2A antagonist MSX-3 reverses the effects of the dopamine antagonist haloperidol on effort-related decision making in a T-maze cost/benefit procedure. Psychopharmacology (Berl). 2009; 204(1):103-12. PMC: 2875244. DOI: 10.1007/s00213-008-1441-z. View